Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects

Bibliography

• McCAFFREY M, BEEBE A: Managing your patients’ adverse reactions to narcotics. Nursing (1989) 19:166-168.
   PubMedGoogle Scholar
• GLARE P, LICKISS JN: Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J. Pain Symptom Manage. (1992) 7:369-371.
   PubMed Web of Science ®Google Scholar
• GOWAN JD, HURTIG JB, FRASER RA, TORBICKI E, KITTS J: Naloxone infusion after prophylactic epidural morphine: effects on incidence of postoperative side-effects and quality of analgesia. Can. J. Anaesth. (1988) 35:143-148.
   PubMed Web of Science ®Google Scholar
• CULPEPPER-MORGAN JA, INTURRISI CE, PORTENOY RK et al.: Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin. Pharmacol. Ther. (1992) 52:90-95.
   PubMed Web of Science ®Google Scholar
• CHESKIN LJ, CHAM TN, JOHNSON RE, JAFFE JH: Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. (1995) 39:151-154.
   PubMed Web of Science ®Google Scholar
• SYKES NP: Using oral naloxone in management of opioid bowel dysfunction. In: Handbook of opioid bowel syndrome. Yuan CS (Ed.), Haworth Medical Press, New York, USA (2005):175-195.
   Google Scholar
• BROWN DR, GOLDBERG LI: The use of quaternary narcotic antagonists in opiate research. Neuropharmacology (1985) 24:181-191.
   PubMed Web of Science ®Google Scholar
• RUSSELL J, BASS P, GOLDBERG LI, SCHUSTER CR, MERZ H: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur. J. Pharmacol. (1982) 78:255-261.
   PubMed Web of Science ®Google Scholar
• BIANCHI G, FIOCCHI R, TAVANI A, MANARA L: Quaternary narcotic antagonists’ relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci. (1982) 30:1875-1883.
   PubMed Web of Science ®Google Scholar
• KOOB GF, PETTIT HO, TTENBERG A, BLOOM FE: Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J. Pharmacol. Exp. Ther. (1984) 229:481-486.
   PubMed Web of Science ®Google Scholar
• KOTAKE AN, KUWAHARA SK, BURTON E, McCOY CE, GOLDBERG LI: Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica (1989) 19:1247-1254.
   PubMed Web of Science ®Google Scholar
• WOODS JH, MEDZIHRADSKY F, SMITH CB, YOUNG AM, SWAIN HH: Annual report: evaluation of new compounds for opioid activity (1980). NIDA Res. Monogr. (1981) 34:327-366.
   PubMedGoogle Scholar
• GMEREK DE, COWAN A, WOODS JH: Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J. Pharmacol. Exp. Ther. (1986) 236:8-13.
   PubMed Web of Science ®Google Scholar
• WALKER MJ, LE AD, POULOS CX, CAPPELL H: Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists. Psychopharmacology (Berl.) (1991) 104:164-166.
   PubMed Web of Science ®Google Scholar
• YUAN CS: Gastric effects of μ-, δ- and κ-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Eur. J. Pharmacol. (1996) 314:27-32.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF: Gastric effects of methylnaltrexone on μ, κ, and δ opioid agonists induced brainstem unitary responses. Neuropharmacology (1999) 38:425-432.
   PubMed Web of Science ®Google Scholar
• MANARA L, BIANCHETTI A: The central and peripheral influences of opioids on gastrointestinal propulsion. Ann. Rev. Pharmacol. Toxicol. (1985) 25:249-273.
   PubMed Web of Science ®Google Scholar
• GMEREK DE, COWAN A, WOODS JH: Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J. Pharmacol. Exp. Ther. (1986) 236:8-13.
   PubMed Web of Science ®Google Scholar
• FERRITTI P, TAVANI A, MANARA L: Inhibition of gastrointestinal transit and antinociceptive effects of morphine and FK-33-824 in rats are differently prevented by naloxone and the N-methyl quaternary analog. Res. Commun. Subst. Abuse (1981) 2:1-11.
   Google Scholar
• YUAN CS, FOSS JF, MOSS J: Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur. J. Pharmacol. (1995) 276:107-111.
   PubMed Web of Science ®Google Scholar
• BORISON HL, WANG SC: Physiology and pharmacology of vomiting. Pharmacol. Rev. (1953) 5:193-230.
   PubMed Web of Science ®Google Scholar
• FOSS JF, BASS AS, GOLDBERG LI: Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J. Clin. Pharmacol. (1993) 33:747-751.
   PubMed Web of Science ®Google Scholar
• FOSS JF, YUAN CS, ROIZEN MF, GOLDBERG LI: Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother. Pharmacol. (1998) 42:287-291.
   PubMed Web of Science ®Google Scholar
• AUNG HH, MEHENDALE S, XIE JT, MOSS J, YUAN CS: Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci. (2004) 74:2685-2691.
   PubMed Web of Science ®Google Scholar
• FOSS JF, O’CONNOR MF, YUAN CS, MURPHY M, MOSS J, ROIZEN MF: Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J. Clin. Pharmacol. (1997) 37:25-30.
   PubMed Web of Science ®Google Scholar
• YUAN CS, DOSHAN H, CHARNEY MR et al.: Tolerability, gut effect, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J. Clin. Pharmacol. (2005) 45:538-546.
   PubMed Web of Science ®Google Scholar
• KIM C, CHENG R, CORRIGALL WA, COEN KM: High-perfomance liquid-chromatography with coulometric electochemical detection. Chromatographia (1989) 28:359-363.
   Web of Science ®Google Scholar
• OSINSKI J, WANG A, WU JA, FOSS JF, YUAN CS: Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J. Chromatogr. B (2002) 780:251-259.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M, TOLEDANO A, ROIZEN MF, MOSS J: Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol. Ther. (1996) 59:469-475.
   PubMed Web of Science ®Google Scholar
• YUAN CS, WEI G, FOSS JF, O’CONNOR M, KARRISON T, OSINSKI J: Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J. Pharmacol. Exp. Ther. (2002) 300:118-123.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, OSINSKI J, TOLEDANO A, ROIZEN MF, MOSS J: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. (1997) 61:467-475.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M et al.: Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. (2000) 67:398-404.
   PubMed Web of Science ®Google Scholar
• AMIN HM, SOPCHAK AM, FOSS JF, ESPOSITO BF, ROIZEN MF, CAMPORESI EM: Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth. Analg. (1994) 78:701-705.
   PubMed Web of Science ®Google Scholar
• GOMERY P, CHEN T, STEFANOVICH P et al.: Antagonism of opioid bladder and pupil effects by methylnaltrexone, naloxone, or placebo. Proc. Intl. Soc. Anesth. Pharm. (2003).
   Google Scholar
• BOND JH Jr, LEVITT MD, PRENTISS R: Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J. Lab. Clin. Med. (1975) 85:546-555.
   PubMed Web of Science ®Google Scholar
• READ NW, AL-JANABI MN, BATES TE et al.: Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate. Gut (1985) 26:834-842.
   PubMed Web of Science ®Google Scholar
• YUAN CS, KARRISON T, WU JA, LOWELL TK, LYNCH JP, FOSS JF: Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. Clin. Pharmacol. Ther. (1998) 63:379-383.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M, ROIZEN MF, MOSS J: Effects of low-dose morphine on gastric emptying in healthy volunteers. J. Clin. Pharmacol. (1998) 38:1017-1020.
   PubMed Web of Science ®Google Scholar
• MURPHY DB, SUTTON JA, PRESCOTT LF, MURPHY MB: Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology (1997) 87:765-770.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M, MOSS J, ROIZEN MF: Gut motility and transit changes in patients receiving long-term methadone maintenance. J. Clin. Pharmacol. (1998) 38:931-935.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M, OSINSKI J, ROIZEN MF, MOSS J: Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain (1999) 83:631-635.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O’CONNOR M et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized, controlled trial. J. Am. Med. Assoc. (2000) 283:367-372.
   PubMed Web of Science ®Google Scholar
• YUAN CS, MOSS J, WEI G, MALECKAR SA, BOYD TA, ISRAEL RJ: Methylnaltrexone for chronic opioid-induced constipation. Proc. Am. Soc. Clin. Oncol. (2002) 21:376a.
   Google Scholar
• YUAN CS, FOSS JF: Oral methylnaltrexone for opioid-induced constipation. J. Am. Med. Assoc. (2000) 284:1383-1384.
   PubMed Web of Science ®Google Scholar
• THOMAS J, PORTENOY RK, MOEHL M et al.: A Phase II randomized dose-finding trail of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. Proc. Am. Soc. Clin. Oncol. (2003) 22:2933.
   Google Scholar
• MEIER DE, MORRISON RS, CASSEL CK: Improving palliative care. Ann. Intern. Med. (1997) 127:225-230.
   PubMed Web of Science ®Google Scholar
• ABRAHAM JL: A physician’s guide to pain and symptom management in cancer patients. Johns Hopkins University Press, Baltimore, USA (2000).
   Google Scholar
• MERCADANTE S: Diarrhea, malabsorption, and constipation. In: Palliative care and supportive oncology. Berger AM, Portenoy RK, Weissman DE (Eds), Lippincott, Williams & Wilkins, Philadelphia, USA (2002):233-249.
   Google Scholar
• BAUER AJ, BOECKXSTAENS GE: Mechanism of postoperative ileus. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):54-60.
   PubMed Web of Science ®Google Scholar
• HUGE A, KREIS ME, ZITTEL TT et al.: Postoperative colonic motility and tone on patients after colorectal surgery. Dis. Colon Rectum (2000) 43:932-939.
   PubMed Web of Science ®Google Scholar
• BASSE L, JAKOBSEN DH, BILLESBOLLE P et al.: A clinical pathway to accelerate recovery after colonic resection. Ann. Surgery (2000) 232:51-57.
   PubMed Web of Science ®Google Scholar
• VISCUSI E, RATHMELL J, FICHERA A et al.: A double-blind, randomized, placebo-controlled trial of methylnaltrexone for post-operative bowel dysfunction in segmental colectomy patients. Proc. Am. Soc. Anesth. (2005):1630.
   Google Scholar
• THOMAS J, LIPMAN A, SLATKIN N et al.: A Phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI). Proc. Am. Soc. Clin. Oncol. (2005) 25:8003.
   Google Scholar
• KEHLET H: Endogenous morphine-another component and biological modifier of the response to surgical injury? Acta Anaesthesiol. Scand. (2000) 44:1167-1168.
   PubMed Web of Science ®Google Scholar
• SCHANG JC, DEVROEDE G: Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am. J. Gastroenterol. (1985) 80:407-411.
   PubMed Web of Science ®Google Scholar
• HOLZER P: Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci. Lett. (2004) 361:192-195.
   PubMed Web of Science ®Google Scholar
• KREEK MJ, SCHAEFER RA, HAHN EF, FISHMAN J: Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet (1983) 1:261-262.
   PubMed Web of Science ®Google Scholar
• HAWKES ND, RHODES J, EVANS BK, RHODES P, HAWTHORNE AB, THOMAS GA: Naloxone treatment for irritable bowel syndrome – a randomized controlled trial with an oral formulation. Aliment. Pharmacol. Ther. (2002) 16:1649-1654.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTY NK, MATALLANA A, JENSEN R, BORISON HL: Central effects of antitussive drugs on cough and respiration. J. Pharm. Exp. Ther. (1956) 117:127-135.
   PubMed Web of Science ®Google Scholar
• ADCOCK JJ, SCHNEIDER C, SMITH TW: Effects of codeine, morphine and a novel opioid pentapeptide BW443C, on cough, nociception and ventilation in the unanaesthetized guinea-pig. Br. J. Pharmacol. (1988) 93:93-100.
   PubMed Web of Science ®Google Scholar
• FOSS JF, ORELIND E, GOLDBERG LI: The effects of methylnaltrexone on morphine-induced cough suppression in guinea-pigs. Life Sci. (1996) 59(15):235-238.
   PubMed Web of Science ®Google Scholar
• PETERSEN TK, HUSTED SE, RYBRO L, SCHURIZEK BA, WERNBERG M: Urinary retention during i.m. and extradural morphine analgesia. Br. J. Anaesth. (1982) 59:1175-1178.
   Web of Science ®Google Scholar
• WEI G, MOSS J, YUAN CS: Opioid-induced immunosuppression: is this a centrally-mediated or peripherally-mediated mechanism? Biochem. Pharmacol. (2003) 65:1761-1766.
   PubMed Web of Science ®Google Scholar
• EISENSTEIN TK, HILBURGER ME: Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. (1998) 83:36-44.
   PubMed Web of Science ®Google Scholar
• HO WZ, GUO CJ, YUAN CS, DOUGLAS SD, MOSS J: Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J. Pharmacol. Exp. Ther. (2003) 307:1158-1162.
   PubMed Web of Science ®Google Scholar
• LEVY JH, BRISTER NW, SHEARIN A et al.: Wheal and flare responses to opioids in humans. Anesthesiology (1989) 70:756-760.
   PubMed Web of Science ®Google Scholar
• BARKE KE, HOUGH LB: Opiates, mast cells and histamine release. Life Sci. (1993) 53:1391-1399.
   PubMed Web of Science ®Google Scholar
• GORDON EM, MYERS C, BLUMER J: In vitro evaluation of the potential role of sulfite radical in morphine-associated histamine release. BMC Pharmacol. (2004) 4:21.
   PubMedGoogle Scholar
• YUAN CS, FOSS JF, OSINSKI J, ROIZEN MF, MOSS J: Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend. (1998) 52:161-165.
   PubMed Web of Science ®Google Scholar
• NEARY P, DELANEY CP: Alvimopan. Expert Opin. Investig. Drugs (2005) 14:479-488.
   PubMed Web of Science ®Google Scholar